XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Xenon Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$35.08+1.59 (+4.75%)
Close on Oct 19, 2026
- Market cap
- $3.49B
- P/E (TTM)
- –
- Dividend yield
- –
Xenon Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $3.40B | $166.30M |
| Enterprise Value | $2.47B | $88.19M |
| PB Ratio | 2.73 | 2.03 |
| P/TBV Ratio | 2.73 | 2.29 |
Income (trailing twelve months)
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $0 | $58.34M |
| Operating Income | -$441.59M | -$21.40M |
| Pretax Income | -$411.14M | -$14.34M |
| Net Income | -$409.20M | -$22.46M |
| EBITDA | -$439.19M | -$16.91M |
| EPS (Diluted) | -$4.74 | -$0.83 |
Returns
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -43.6% | -53.2% |
| Return on Assets (ROA) | -41.5% | -40.9% |
| Return on Invested Capital (ROIC) | -152.3% | -32.4% |
| Return on Capital Employed (ROCE) | -35.3% | -38.1% |
Growth
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -100.0% | 5.96% |
| Revenue Growth (3Y CAGR) | -7.36% | 2.25% |
| Revenue Growth (5Y CAGR) | -25.3% | 6.48% |
Balance sheet
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $930.69M | $61.43M |
| Net Cash (Debt) | $930.69M | $15.35M |
| Net Cash Per Share | $9.61 | $0.66 |
| Equity (Book Value) | $1.24B | $49.09M |
| Book Value Per Share | $12.83 | $1.37 |
| Tangible Book Value | $1.24B | $23.52M |
| Working Capital | $900.86M | $76.81M |
Financial position
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 21.02 | 3.34 |
| Quick Ratio | 20.68 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$337.52M | -$12.35M |
| Capital Expenditures | -$1.01M | -$1.08M |
| Free Cash Flow | -$338.53M | -$20.22M |
| FCF Per Share | -$3.50 | -$0.42 |
Efficiency
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $0 | $404.87K |
| Profits Per Employee | -$1.11M | -$703.34K |
| Employee Count | 370 | 74 |
Dividends and yields
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -12.0% | -23.3% |
| FCF Yield | -9.96% | -8.72% |
Shares
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 96,840,400 | 58,127,000 |
| Shares Change (YoY) | 10.3% | 10.9% |
| Shares Change (QoQ) | 0.13% | 0.54% |
| Float | 96,726,500 | 49,136,700 |
| Shares Held by Insiders | 0.12% | 11.6% |
| Shares Held by Institutions | 104.4% | 59.4% |
Taxes
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$1.94M | $79.87K |
Scores
| Measure | Xenon Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 36.32 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Xenon Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.